MDA (Medical Devices Agency) head offers the glass half full approach in regulatory matters
This article was originally published in Clinica
Clinica's European regulatory affairs editor, Amanda Maxwell, went to visit David Jefferys, chief executive of one of Europe's most influential medical device regulatory authorities, the UK's Medical Devices Agency in London. He is widely tipped to head up UK the pharmaceutical regulatory unit too. Clinica's agenda: to find out more about the forthcoming medicines and medical device agency and to ascertain whether the tipsters are right I found David Jefferys in an upbeat mood when I visited his offices on the 20th floor of the Elephant & Castle building, a monstrosity viewed from the outside in an unfashionable area of London, but which affords breathtaking views over the capital. My intention was to unearth more about the politics underpinning the merger between the UK medicines and devices agencies, "world leaders" in their fields, as Dr Jefferys described them. I had read the press release, couched in the usual positive government-speak, but the suddenness of statement about the merger between the MDA and the MCA, which seemed to take everyone by surprise, suggested there was something more to this story.